Abstract
Systemic intravenous epoprostenol, as well as being a vasodilator, is the most potent inhibitor of platelet aggregation known. Early research carried out on its use in microvascular surgery showed promising results in preventing thrombosis and improving flap survival rates, however interest in its use in microsurgery has diminished in recent years. In this report we describe its use in successful free flap salvage and discuss its role in microsurgery.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
